ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. GlaxoSmithKline's annualized return on capital (ROC %) for the quarter that ended in Sep. 2016 was 58.87%.
As of today (2026-06-30), GlaxoSmithKline's WACC % is 0.00%. GlaxoSmithKline's ROC % is 0.00% (calculated using TTM income statement data).
GlaxoSmithKline earns returns that do not match up to its cost of capital. It will destroy value as it grows.
GlaxoSmithKline (CAI:BIOC) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, GlaxoSmithKline's WACC % is 0.00%. GlaxoSmithKline's ROC % is 0.00% (calculated using TTM income statement data).
GlaxoSmithKline earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
GlaxoSmithKline ROC % Related Terms
GlaxoSmithKline ROC % Historical Data
* Premium members only.
The historical data trend for GlaxoSmithKline's ROC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is four times the quarterly (Sep. 2016) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline (CAI:BIOC) has a ROC % of 58.87% as of Sep. 2016. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's ROC % too high?
GlaxoSmithKline's current ROC % is 58.87%. The Drug Manufacturers industry median ROC % is 4.46. GlaxoSmithKline's value of 58.87% is 1220% above this industry median.
How does GlaxoSmithKline's ROC % compare to PRPH?
GlaxoSmithKline's ROC % of 58.87% can be compared against companies in the Drug Manufacturers industry. The industry median ROC % is 4.46. GlaxoSmithKline's value of 58.87% is 1220% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Drug Manufacturers company?
The median ROC % among Drug Manufacturers companies is 4.46, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline's current ROC % of 58.87% is 1220% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on GlaxoSmithKline and its competitors. For the Drug Manufacturers industry, the median ROC % is 4.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline's current ROC % is 58.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current ROC % of 58.87%. The current ROC % is 58.87% and 1220% above the Drug Manufacturers industry median of 4.46. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current ROC % is 58.87% as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:BIOC has been successfully added to your 